Scarica l'app Stockscreener
61.10
5.07%
-3.26
Pre-mercato:
61.40
0.30
+0.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$64.36
Aprire:
$65.03
Volume 24 ore:
643.08K
Relative Volume:
0.92
Capitalizzazione di mercato:
$2.31B
Reddito:
-
Utile/perdita netta:
$-91.00M
Rapporto P/E:
-16.65
EPS:
-3.67
Flusso di cassa netto:
$-74.38M
1 W Prestazione:
-8.66%
1M Prestazione:
-25.17%
6M Prestazione:
+1.51%
1 anno Prestazione:
+10.41%
Intervallo 1D:
$60.92
$65.03
Intervallo di 1 settimana:
$60.92
$68.19
Portata 52W:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Nome
Disc Medicine Inc
Settore
Industria
Telefono
(617) 674-9274
Indirizzo
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
61.10 | 2.43B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Ripresa | Stifel | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-11 | Ripresa | Raymond James | Strong Buy |
| 2025-02-27 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-01 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-17 | Iniziato | Raymond James | Outperform |
| 2023-04-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Iniziato | Stifel | Buy |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2023-03-23 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Disc Medicine Inc Borsa (IRON) Ultime notizie
Insider Sell: William Savage Sells Shares of Disc Medicine Inc (IRON) - GuruFocus
William Jacob Savage Sells 7,378 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst - AOL.com
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection - AOL.com
IRON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IRON: Multiple late-stage programs advance toward pivotal data and regulatory milestones in 2024 - TradingView
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - MarketBeat
Disc Medicine, Inc. (IRON) Stock Analysis: A 50% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
IRON (NASDAQ: IRON) proposed insider sales including 13,093-share 12/15/2025 sale - Stock Titan
Watertown biotech cuts 20% of staff after FDA rejects rare disease drug - The Business Journals
IRON: Wells Fargo Raises Price Target for Disc Medicine | IRON S - GuruFocus
Disc Medicine (NASDAQ:IRON) Price Target Raised to $79.00 - MarketBeat
Disc Medicine Refocuses On APOLLO Trial After FDA Letter For Bitopertin - Sahm
Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf RegistrationWhat's Changed - Yahoo Finance
A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings - Sahm
Disc Medicine (IRON) Announces Restructuring Following FDA Setba - GuruFocus
Disc Medicine announces workforce reduction and restructuring plan By Investing.com - Investing.com Australia
Disc Medicine announces workforce reduction and restructuring plan - Investing.com Nigeria
Insider Sell: Jean Franchi Sells Shares of Disc Medicine Inc (IR - GuruFocus
Disc Medicine (NASDAQ:IRON) CFO Sells $24,378.18 in Stock - MarketBeat
Disc Medicine Implements Restructuring Following FDA Response - TipRanks
Disc Medicine's board approves restructuring plan - marketscreener.com
Disc Medicine (IRON) CFO sells 353 shares under 10b5-1 plan - Stock Titan
Disc Medicine (IRON) trims workforce 20% after FDA letter, books $2M charge - Stock Titan
Disc Medicine (NASDAQ:IRON) Price Target Lowered to $83.00 at Truist Financial - MarketBeat
JPMorgan Chase & Co. Sells 90,737 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight - GuruFocus
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results - MarketBeat
Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Disc Medicine's 2025 Net Loss Widens - marketscreener.com
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Disc Medicine, Inc. SEC 10-K Report - TradingView
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Disc Medicine's 2025 net loss smaller than estimates - TradingView
Disc Medicine (NASDAQ: IRON) faces FDA CRL as hematology pipeline advances - Stock Titan
Disc Medicine (NASDAQ: IRON) details 2025 loss, cash runway and FDA letter - Stock Titan
After FDA setback, Disc Medicine pushes rare blood drugs with $791M cash - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - AOL.com
Jean Franchi sells 7,081 IRON shares under 10b5-1 (IRON) - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - The Motley Fool
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients - TipRanks
Opinion | Who’s in Charge at the FDA? - WSJ
IRON SEC FilingsDisc Medicine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Shorts: Should I invest in Disc Medicine Inc before earningsPortfolio Value Summary & Free Community Consensus Stock Picks - baoquankhu1.vn
Disc Medicine, Inc. (IRON) Stock Analysis: A High-Risk, High-Reward Play with 61.59% Potential Upside - DirectorsTalk Interviews
Disc Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Disc Medicine lines up four investor events in March - Stock Titan
Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4 - MarketBeat
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route - AOL.com
Disc Medicine Inc Azioni (IRON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):